ZyVersa Therapeutics, a biopharmaceutical company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment, submitted on May 15, 2024, addresses and restates certain sections of the original Form 10-K to clarify language and update the exhibit list. The company's financial statements were not included in this amendment, and no new financial data was provided. ZyVersa, which is listed on the Nasdaq Capital Market under the symbol ZVSA, has identified a material weakness in its internal control over financial reporting, specifically in business process controls. Despite this, the company believes its financial statements fairly present its financial position. As an emerging growth company, ZyVersa is utilizing certain exemptions from public company reporting requirements, including not having its...Show More

ZyVersa Therapeutics, a biopharmaceutical company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment, submitted on May 15, 2024, addresses and restates certain sections of the original Form 10-K to clarify language and update the exhibit list. The company's financial statements were not included in this amendment, and no new financial data was provided. ZyVersa, which is listed on the Nasdaq Capital Market under the symbol ZVSA, has identified a material weakness in its internal control over financial reporting, specifically in business process controls. Despite this, the company believes its financial statements fairly present its financial position. As an emerging growth company, ZyVersa is utilizing certain exemptions from public company reporting requirements, including not having its internal control over financial reporting audited as per Section 404(b) of the Sarbanes-Oxley Act. The company has committed to remediation plans to address the identified material weakness, with expectations to complete these during 2024. ZyVersa's market value as of June 30, 2023, was approximately $5.6 million, with 834,896 shares of common stock outstanding as of May 10, 2024.